OER‐073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34403
Abstract: Angiosarcomas are rare mesenchymal sarcomas that can present as primary cutaneous or noncutaneous disease. They express a variety of vascular endothelial growth factor receptors. The authors hypothesized that the treatment of angiosarcoma with pazopanib, a… read more here.
Keywords: oer 073; pazopanib; 073 multicenter; multicenter phase ... See more keywords